NPPB and hydrops fetalis: Vericiguat efficacy was maintained until NT-proBNP levels of 8000 pg/mL, which correspond to 86% of the population (adjusted HR: 0.85; 95% CI: 0.76–0.95 for primary endpoint; adjusted HR: 0.84; 95% CI 0.71–0.99 for cardiovascular death; adjusted HR: 0.84; 95% CI: 0.75–0.95 for HF-related hospitalizations).